Exome sequencing of index patients with retinal dystrophies as a tool for molecular diagnosis. by Corton, M. et al.
Exome Sequencing of Index Patients with Retinal
Dystrophies as a Tool for Molecular Diagnosis
Marta Corton1., Koji M. Nishiguchi2., Almudena Avila-Ferna´ndez1, Konstantinos Nikopoulos2,
Rosa Riveiro-Alvarez1, Sorina D. Tatu1, Carmen Ayuso1", Carlo Rivolta2*"
1Department of Genetics, IIS- Fundacion Jimenez Diaz, CIBERER, Madrid, Spain, 2Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland
Abstract
Background: Retinal dystrophies (RD) are a group of hereditary diseases that lead to debilitating visual impairment and are
usually transmitted as a Mendelian trait. Pathogenic mutations can occur in any of the 100 or more disease genes identified
so far, making molecular diagnosis a rather laborious process. In this work we explored the use of whole exome sequencing
(WES) as a tool for identification of RD mutations, with the aim of assessing its applicability in a diagnostic context.
Methodology/Principal Findings: We ascertained 12 Spanish families with seemingly recessive RD. All of the index patients
underwent mutational pre-screening by chip-based sequence hybridization and resulted to be negative for known RD
mutations. With the exception of one pedigree, to simulate a standard diagnostic scenario we processed by WES only the
DNA from the index patient of each family, followed by in silico data analysis. We successfully identified causative mutations
in patients from 10 different families, which were later verified by Sanger sequencing and co-segregation analyses.
Specifically, we detected pathogenic DNA variants (,50% novel mutations) in the genes RP1, USH2A, CNGB3, NMNAT1, CHM,
and ABCA4, responsible for retinitis pigmentosa, Usher syndrome, achromatopsia, Leber congenital amaurosis,
choroideremia, or recessive Stargardt/cone-rod dystrophy cases.
Conclusions/Significance: Despite the absence of genetic information from other family members that could help
excluding nonpathogenic DNA variants, we could detect causative mutations in a variety of genes known to represent a
wide spectrum of clinical phenotypes in 83% of the patients analyzed. Considering the constant drop in costs for human
exome sequencing and the relative simplicity of the analyses made, this technique could represent a valuable tool for
molecular diagnostics or genetic research, even in cases for which no genotypes from family members are available.
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Introduction
Retinal dystrophies (RD), comprising the wide spectrum of
retinal degeneration, are rare genetic conditions leading to visual
deficiency and in some instances to blindness [1]. These diseases
affect roughly one person out of 4,000 and are the result of the
progressive loss or dysfunction of photoreceptors, the light-sensing
cells of the eye [2]. RD are caused by mutations in more than 100
different genes (RetNet; https://sph.uth.edu/Retnet/home.htm).
Mutations causing RD can occur in any of these genes, as well as
in other disease genes that still await identification, and can be
transmitted as dominant, recessive, or X-linked alleles. This very
elevated genetic heterogeneity is possibly the highest detected so
far among all Mendelian diseases and leads to a very high carrier
frequency of heterozygous mutant alleles, i.e. possibly more than 1
in 4–5 individuals [3]. Molecular diagnosis is therefore an
extremely daunting task since unrelated patients with the similar
clinical presentations are likely to have defects in different genes,
each of which with a small chance to be found positive for
mutations. In other cases, accurate molecular diagnosis is
hampered by limited clinical information, which is critical for
efficiently deciding which genes have to be analyzed. To bypass
the drawbacks of classical exon-by-exon PCR screenings, associ-
ated with very long processing times, the use of mutation- or gene-
specific microarrays has been recently adopted [4–12], with
different results reported by us and others to be largely dependent
on the characteristics of the population screened [13–19].
Whole exome sequencing (WES) is a procedure that allows the
purification by sequence capture of all exonic regions of a genome
and their further processing by next-generation sequencing (NGS)
[20]. Since the selection of the target regions to be sequenced by
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WES spans all of the genome, this method is not conventionally
used to interrogate a specific DNA fragment or a limited number
of genes, but conversely it is adopted to investigate genetic features
at a genome scale. Moreover, in virtue of their general
applicability, WES protocols and kits have diffused rapidly and
have become more and more affordable, to the point of being in
some instances less expensive than targeted DNA capture/NGS
projects interrogating a lower number of DNA features.
In this work, we evaluate the possibility of using WES as a tool
for routine molecular diagnoses in patients with apparently
recessive RD. Although we specifically selected families with
multiple affected members to allow validation of the findings, we
willingly ignored the information related to the pedigree, to
simulate the use of this technique for the large majority of people
with RD, i.e. isolate patients.
Materials and Methods
Ethics Statement
This study was carried out in accordance with the tenets of the
Declaration of Helsinki and was approved by the Institutional
Review Boards of the University of Lausanne and the Clinical
Research Ethics Committee of the Fundacion Jimenez Diaz.
Written informed consent for WES analyses was obtained from the
subjects who participated in this study and donated their blood for
research. Each individual was anonymized by assigning to him/
her a numeric ID; confidentiality and protection of data were
ensured by applying international recommendations and current
Spanish legislation (Ley de Investigacion Biomedica 14/2007 and
LOPD).
Patients
All patients were previously tested and all resulted to be negative
for known autosomal recessive retinitis pigmentosa (ARRP) or
Leber Congenital Amaurosis (LCA) mutations by microarray
screening, based on the Arrayed Primer EXtension (APEX)
technology [Asper Ophthalmics, Tartu, Estonia] [21]. Seven
families (RP-0137, RP-0298, RP-0461, RP-1102, RP-1116, RP-
1164, RP-1263) were also analyzed by whole genome homozy-
gosity mapping using SNP arrays from Affymetrix (Genome Wide
Human SNP array 6.0 and GeneChip Human Mapping 500K
Array Set) or Illumina (HumanLinkage V Panel Set or Omni
Whole Genome arrays HumanCytoSNP-12), as previously
described [22]. Affymetrix genotyping services were provided by
the Spanish ‘‘Centro Nacional de Genotipado’’ (CEGEN-ISCIII).
No significant homozygous regions larger than 1 Mb were found
in these families. Only index patients from each family were
analyzed by WES, except for family RP-0235, for which all 5
members underwent WES analyses.
Sample Preparation
Genomic DNA was extracted from 7 ml of whole blood using
an automated DNA extractor (BioRobot EZ1 Qiagen, Hilden,
Germany) following the manufacturer’s instructions.
Library Preparation and Sequencing
Purification of target sequences, library preparation, and NGS
processing was performed by BGI-Shenzen (Shenzhen, China), as
previously described [23].
Alignment and Analysis of Reads
Reads were mapped to the human genome reference sequence
(NCBI build 36.1) and call of variants was performed according to
previously published algorithms and procedures [24]. These
procedures were performed by BGI, under a fee-for-service
agreement.
Filtering Procedures of Detected Variants
DNA variants identified following mapping and evaluation of
the reads were assessed to represent actual RD mutations by a 5-
step filtering procedure, mainly by the use of simple Perl scripts
developed in house and available upon request and/or by the use
of standard electronic spreadsheets. First, all variants that were not
part of coding sequences or represented silent changes were
eliminated, to produce a set of DNA changes that would include
only missense, nonsense, and indel events, as well as substitutions
affecting exon splicing signals. A second step consisted of selecting
only variations found to affect 160 known RD genes. The number
of remaining variants was then further reduced by removing
known SNPs that were present in dbSNP version 130 (a version
that is devoid of data from large-scale endeavors) and having an
allelic frequency higher than 0.02. Subsequently, a fourth filtering
procedures consisted in ascertaining RD genes carrying two of
these variants (or the same variant, but homozygously) to account
for the recessive mode of inheritance. At this point, all candidate
variants were carefully checked for previous description in the
literature and databases, including dbSNP version 137.
PCR and Sanger Sequencing
Variants detected by NGS and suspected to be pathogenic were
re-amplified by PCR by using as a template an aliquot of the same
DNA samples that were used for WES. Cycling conditions and
primers used are listed in Table S1. PCR products were
enzymatically purified using ExoSAP-it (USB, Affymetrix, Santa
Clara, CA) and sequenced on both strands using the Big Dye
Terminator Cycle Sequencing Kit v3.1 Kit (Applied Biosystems).
The sequence products were purified on a 96-well multiscreen
filter plate (Montage SEQ96 Sequencing Reaction Cleanup Kit,
Millipore, Bedford, MA) and resolved on a 3130xl ABI instrument
(Applied Biosystems). Chromatograms were interpreted and
aligned to the human reference sequence using the STADEN
package [25].
Results
Ascertainment of Patients
Twelve Spanish families with recessive RD were ascertained.
Diagnoses were based on ophthalmologic examination and
pedigree data, according to previously described/established
clinical and classification criteria [26–30]. Clinical findings of
these patients are summarized in Table S2.
Detection and Filtering of DNA Variants
The number of variants remaining after the application of each
of the five filtering processes is summarized in Table S3. In short,
we detected on average 67,000 DNA variants per genome. Of
these, only ,12,000 represented changes that could potentially
alter the sequence or the structure of coding transcripts. Among
them, 108 to 143 variants were present in the 160 genes that were
previously found to cause RD and 18 to 34 were rare changes (less
than 2% in frequency) or were not registered in dbSNP 130. The
few variants that were identified as 2 alleles (either as a compound
heterozygote with another variant or as a homozygote) in a single
RD gene and thus could account for the recessive inheritance
pattern were further analyzed.
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Detection of Mutations in Known RD Genes
Ten of the 12 index patients analyzed by WES were found to be
either homozygous or compound heterozygous for variants in
known RD genes that would satisfy our filtering criteria (Table 1,
Figure 1).
More specifically, 3 patients/families were positive for muta-
tions in ABCA4, 2 had mutations in the RP1 gene, and 2 others in
the CNGB3 gene. The remainder of these carried variants in CHM,
USH2A, and NMNAT1. All of these mutations cosegregated
perfectly with the disease in all families, according to a recessive or,
in the case of family RP-1164, X-linked pattern of inheritance, as
ascertained by exon-PCR and Sanger sequencing (Figure 1). Of
the 15 different mutations identified, 8 were never described
previously and included 7 changes that were clearly deleterious
alleles (frameshifts or nonsenses, Table 1). The remaining
mutation was a missense change (c.12574C.T, p.R4192C)
identified in the USH2A gene. This was considered pathogenic
in conjunction with another clear-cut mutation
(c.920_923dupGCCA, p.H308Qfs*16) based on the following
reasons. First, cosegregation analysis in the mother and 5 other
siblings (2 affected and 3 unaffected) was statistically significant,
with a p-value of 0.006 (Figure 1). Second, the mutation was not
found in 100 ethnically-matched healthy controls or any other
public database, including the one from the 1000 Genomes
Project. Lastly, in silico assessment of the consequence of the
Figure 1. Pedigrees of patients analyzed and mutations identified in this work. The family ID is given above the pedigree, while the
individuals’ IDs are indicated below the symbols depicting them. Red circles indicate individuals whose DNA underwent WES analysis. The name of
the RD gene identified as causative of the disease is given in blue. M/M, homozygous mutation; M/m compound heterozygous mutations.
doi:10.1371/journal.pone.0065574.g001
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missense mutation predicted the change to affect the function of
the translated protein (SIFT and Polyphen).
All patients identified with disease-associated mutations had no
other genes/variants that fulfilled our filtering criteria, except for
individual 04/0834. This patient carried the previously-reported
homozygous CNGB3 mutation p.T383Ifs*13 [31] but was also
found to have two novel missense variations in the USH2A gene.
Sanger sequencing failed to detect one of such USH2A variants
(thus representing a false negative result) while the presence of the
homozygous mutation in CNGB3 was confirmed.
The remaining 2 index patients from families RP-0886 and RP-
0461 were not identified with pathogenic RD mutations. They
were therefore all considered as patients for whom molecular
diagnosis could not be achieved in absence of additional
information.
Discussion
Because of the elevated genetic and allelic heterogeneity
displayed by hereditary retinal degenerations, molecular diagnoses
are in general a rather complicated task. Although precise clinical
information or family history can facilitate this procedure, the
number of known mutations that medical geneticists have to
consider in the screening process is likely in the range of a few
thousands, over more than 100 different genes. For example,
approximately 600 variants/mutations in the USH2A gene alone
have been reported so far (the USH2A mutations database:
http://www.lovd.nl/USH2A). Furthermore, novel RD mutations
are constantly being discovered, reducing the value of semi-
automated analyses interrogating a specific set of DNA variants.
Starting from the evidence that costs of whole-exome sequenc-
ing are constantly lowering and that this technique, although not
too sensitive, allows an unsupervised analysis of all of the coding
sequences of the human genome, we reasoned that WES could in
fact be used in routine DNA-based diagnosis of RD. Our results
show an 83% success rate, over 12 families with seemingly
recessive RD. This high success rate can partially be explained by
the nature itself of recessive conditions, for which two mutations
have to be present in the same gene to cause disease. This event
alone enables a drastic reduction of the noise associated with
WES, since the likelihood that two false negative results (e.g. real
DNA changes with no pathogenic effects or simple sequencing
errors) affect by chance the same gene is very low. In dominantly
inherited cases, for which such a filter cannot be applied, there
would be a priori no such a way of distinguishing pathogenic
variants form rare DNA changes or sequencing false calls.
However, although with lower efficiency, WES could in principle
still be applied. Important success factors in dominant investiga-
tions would be represented by the detection of clear-cut mutations,
such as indels and nonsense variants, in known disease genes and
the use of control population data analyzed with WES, in order to
systematically subtract the noise and enhance the signal through-
out the genome. Additionally, the identification of less striking but
previously-reported pathogenic changes would also suffice to
provide molecular diagnoses to dominant RD cases. For instance,
we could efficiently detect a novel frameshift mutation in the CHM
gene in a male patient with choroideremia. Since CHM is located
on the chromosome X, this patient and his affected brother do in
fact carry a single causative mutation, as in individuals affected by
autosomal dominant conditions. Isolated RD cases would be, in
the vast majority of the circumstances, either unrecognized
recessive cases or de novo dominant cases, and therefore could be
analyzed by following the same procedures.
NGS has been applied previously to screen for specific forms of
RD, with variable results [32–34]. For example, NGS provided
genetic diagnosis in 36% (36 out of 100) of patients with retinitis
pigmentosa [33]. After correcting for the mutation detection rate
of NGS and by taking into consideration previously solved cases,
the diagnostic yield increased to ,50%. The comparatively
favorable results of the current study that identified 83% of the
causes of RD may be attributable to a few specific elements,
including the size of the cohort analyzed, the methods and
extensiveness of the genetic screenings carried out in the past, the
Table 1. RD mutations identified by WES analyses.
FAMILY ID INDEX PATIENT ID GENE (OMIM entry) NUCLEOTIDE CHANGE PROTEIN CHANGE NOVEL/KNOWN REFERENCE
RP-0674 01-0570 ABCA4 c.287delA p.N96Tfs*19 novel
(601691) c.6148G.C p.V2050L known [43]
RP-0298 95-0103 ABCA4 c.4720G.T p.E1574* known [44]
c.950delG p.G317Afs*57 novel
RP-1102 07-0366 ABCA4 c.2285C.A (homoz) p.A762E known [45]
RP-1164 07-0360 CHM
(300390)
c.863dupA p.M289Y*18 novel
RP-1263 08-0177 USH2A c.920_923dupGCCA p.H308Qfs*16 known [46]
(608400) c.12574C.T p.R4192C novel
RP-1659 10-1367 CNGB3 c.1148delC p.T383Ifs*13 known [31]
(605080) c.1666G.T p.E556* novel
RP-1174 04-0834 CNGB3 c.1148delC (homoz) p.T383Ifs*13 known [31]
RP-0137 1601 RP1 c.1625C.G p.S542* novel
(603937) c.4804C.T p.Q1602* novel
RP-0235 2343 RP1 c.5173C.T (homoz) p.Q1725* novel
RP-1116 06-1075 NMNAT1 c.507G.A p.W169* known [47]
(608700) c.769G.A p.E257K known [47]
doi:10.1371/journal.pone.0065574.t001
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clinical phenotype of the patients, and/or the sequencing/
mapping methods of NGS itself.
Another element of note is that out of the 15 mutations
identified, 8 (,50%) were novel, despite the genes in which they
were identified were extensively screened for mutations in other
cohorts of patients. This finding confirms, unfortunately, the
limited value of mutation-based microarrays or sequencing
procedures (such as pyrosequencing) in the context of genetics of
RD. We also found that wide phenotypic variability of RD and
limited clinical information could preclude accurate clinical
diagnosis that is essential for current targeted screening methods.
In this context, the ‘‘screen all RD genes’’ approach has certainly
benefitted three of our cases, initially diagnosed as undefined RD
(patient 10/1367), LCA (patient 04/0834), or RP (patient 07/
0360), but having mutations in CNGB3 and CHM causing
achromatopsia and choroideremia, respectively, that would be
missed by ARRP or LCA genotyping microarray. Following such
findings, these patients were re-evaluated clinically, and confirmed
to have achromatopsia and choroideremia.
Despite the power of WES, validation by Sanger sequencing
and, if possible, of additional genetic investigation in family
members of the patient remain key elements for the success of this
screening technique. The value of familial analyses is particularly
evident when we consider the two families for which a DNA
diagnosis could not be reached. In these pedigrees, the number of
candidate mutations in non-reported RD genes was simply too
elevated and, in absence of an additional filtering based on co-
segregation of disease and DNA changes in affected relatives,
could not be reduced. Moreover, due to limitations that are
intrinsic to the exome sequencing procedure, our analyses were
underpowered to score DNA copy number variations (CNVs). It is
therefore possible that these unsolved cases may in fact carry
pathogenic CNVs in RD genes that we were unable to detect.
Methodologically, the procedures used were in general rather
simple. We outsourced the sequencing to a large sequencing
company, which provided us not only with the raw sequencing
reads, but also with an annotated list of variants. These services
represent nowadays a standard offer of many private sequencing
centers as well as of internal genetic facilities, since most WES
protocols and downstream analyses can be streamlined to what
closely resembles routine procedures. Computer-based data
analysis was also not particularly complicated; we mostly used
simple text-parsing scripts and/or commercial spreadsheet pro-
grams with filtering capabilities, on common desktop computers.
In our screening we could also gain a few elements of
information concerning the molecular pathology of RD
mutations. Specifically, we could confirm that missense muta-
tions in USH2A, a gene found to be mutated in patients
suffering from the blindness-deafness disease known as Usher
syndrome, cause in general retinitis pigmentosa without hearing
loss (patient 08–177) [35]. We also confirmed that RP1, a gene
that has been for a long time associated with dominant retinitis
pigmentosa, can in fact carry recessive mutations, as previously
reported [22,36–42].
In summary, in our work we show that whole-exome
sequencing could represent a useful tool for molecular diagnosis
of hereditary retinal degeneration, a disease for which standard
screening procedures still struggle to produce information in a
cost- or time-efficient manner. Further reduction in prices and
improvement in sensitivity and specificity, already in progress,
would probably make of WES the technique of choice for all
future routine DNA diagnoses.
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